33 year followup
1) Stage 1 and 2 NASH no increase in mortality
3) Stage 3 , 4 NASH marked increase in mortality
Firat time proved prospectively..Late stage disease is key- 6 million with late disease, 1 million with cirrhosis
ready for P2.
Two designs with fast track via FDA
June 2015 NASH with cirhosis
July 2nd trial
IF Galt gets its act together, a big IF, and shows positive preliminary data, it could fly.
Dilution is probable, I agree.
One more point, there is no reason to presume that GALT could not be synergistic with any other therapies being developed.
Quick buck won't be found here.